Award Data

The goal of this workis to establish a radiation-aware capability in a commercial EDA design flow that will enable first-pass success in radiation resiliency for DoD ASIC designs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications.Such an integrated capability does not presently exist.The ...

For effective protection against radiated threats, it is important to understand not only the physics of the threats, but also to quantify the effects they have on mission-critical electrical systems. Radiated vulnerability and susceptibility testing requires delivery of high peak power and peak electric fields to distant targets. The most practical solution to simulate such environments on large ...

The Defense Threat Reduction Agency (DTRA) has been supporting research of energetic materials and incendiaries as payloads for weapons to defeat targets containing chemical and biological agents. Several universities and Navy labs have been involved in this research, and have narrowed down on a few material formulations that are efficient biocides. These formulations contain a chemical ingredient ...

Future vaccine development should focus on rapid upscale production, long-term and broad protection, and sufficient global distribution to prevent and reduce the impact of many infectious diseases and potential epidemics. Agave BioSystems proposes to develop a novel whole-microorganism vaccine inactivation strategy involving high-throughput screen of extensive radio-protectant matrices and radiati ...

With missions surrounding counterproliferation, nonproliferation and WMD reduction, the stakes for DTRA are incredibly high. Effectively conducting this work involves cooperation and coordination across a wide range of military and government organizations throughout the United States and the world. The decentralization of threats has led to an explosion in the sources and types of data needed to ...

There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...